A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
Completed
Shire
Phase 3
2009-07-16
This study is being conducted to evaluate the efficacy and safety of icatibant compared to
placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
Completed
Jerini AG
Phase 3
2009-09-25
This study is being conducted to explore the clinical safety, local tolerability, convenience
and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous
injections of icatibant.
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
Completed
Shire
Phase 3
2009-09-25
This study is being conducted to explore the clinical safety, local tolerability, convenience
and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous
injections of icatibant.
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Completed
Shire
Phase 3
2012-01-27
HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the
Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single
subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with
Hereditary Angioedema (HAE) during an initial acute attack.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
